Penghua CSI HK Connect Health Care Composite ETF

Hospital Authority Converts Certain Drugs to Specialized and Includes New Drugs in Medicine Register

Hong Kong Government Announces Increased Healthcare Budget and Implementation of Multiple Measures for 2026-27 Fiscal Year

Hong Kong NPC Deputies Emphasize Aligning with National Strategy to Promote Medical Innovation and International Medical Hub Development

01011

513700

512290

159849

159992

516930

520880

516500

China NT Pharma Group Co., Ltd. disclosed details regarding the resignation of independent non-executive director Mr. Ng Ming Kwan, who cited governance issues and lack of involvement in key transactions as reasons for his departure. He raised concerns about the accuracy of disclosures and internal compliance processes. The board noted that Mr. Ng's statement reflects his views and is reviewing the issues he raised, indicating potential ongoing scrutiny of governance and compliance practices.

Tip Ranks

NT PHARMA

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Universal 800 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

588130

159837

159316

520500

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

09995

688331

159102

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

REMEGEN

RemeGen

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

02268

WXXWY

02269

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

prnewswire

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

iShares US Pharma

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

BlackRock, Inc.

Proshares UltraShort Nasdaq Biotech

Microbiotica reports positive results for MB097 in advanced melanoma

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

Hwabao WP CSI Pharmaceuticals ETF

TransThera reports promising tinengotinib results in advanced solid tumors

01952

On May 14, 2026, Wei Fu, a substantial shareholder of Everest Medicines, purchased 660,000 shares for approximately HK$20.7 million, marking his second acquisition this year. His previous purchase was on March 27, acquiring 860,000 shares. These actions reflect his confidence in the company's strategic direction and operational achievements, as Everest aims for over RMB15 billion in revenue by 2030. The company reported a 142% revenue increase in 2025, achieving profitability for the first time and strong sales in its innovative drugs.

Asian Corporate Newswire

EVEREST MED

Yinhua CNI HK Connect Innovative Drugs ETF

Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

A new clinical study published in Nature Communications highlights the effects of Efsubaglutide Alfa, a GLP-1 receptor agonist, on glycaemic control and β-cell function in adults with type 2 diabetes inadequately controlled on metformin. The SUPER 2 trial demonstrated significant improvements in HbA1c and other glycaemic measures, with a safety profile consistent with the GLP-1 class. The findings suggest that Efsubaglutide Alfa may also improve β-cell function, indicating potential long-term benefits beyond glycaemic control. Innogen Pharmaceuticals led the study, emphasizing the importance of mechanistic insights in developing therapies for metabolic diseases.

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

INNOGEN-B

23:47 ETNew Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

02509

603259

517110

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WUXI APPTEC

SKB BIO

TEDA BIOMEDICAL

INNOVENT BIO

Guotai CSI Hugangshen Innovative Drugs Industry ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

06929

562600

159898

159883

Yesterday's closing price for ORBUSNEICH was HKD 4.5, with a trading volume of approximately HKD 6.85 million, which is considered a normal level of activity among small and mid-cap medical device stocks. The MACD daily line formed a golden cross above the zero axis, a signal typically viewed as a technical confirmation of a shift in the short-term trend from consolidation to a bullish bias, indicating that buying power is gathering in phases. From recent trends, the stock price has gradually stabilized and rebounded from previous lows, with short-term moving averages beginning to turn upward. On the news front, the medical device sector has recently received multiple policy benefits. The domestic medical equipment upgrade policy continues to advance, coupled with the logic of going overseas, leading to increased attention on Hong Kong-listed medical supplies. Major stocks in the pharmaceutical sector, such as Innovent Biologics and CanSino Biologics, maintain high trading levels, indicating that capital enthusiasm for the healthcare sector remains strong. ORBUSNEICH focuses on the field of coronary intervention devices, and under the dual drive of domestic substitution and overseas expansion, the industry's prosperity is expected to continue to rise. From a technical perspective, the area around HKD 4.5 is an important consolidation platform for ORBUSNEICH recently, and the appearance of the MACD golden cross suggests that the balance between bulls and bears is tilting towards the bulls. Short-term moving averages have started to turn upward from a flat position; if there is a subsequent volume breakout above recent highs, the upward space is expected to further open up. However, the current trading volume of HKD 6.85 million is still relatively low, and signs of large capital entering the market are not yet apparent. In terms of risk, small-cap medical device stocks have limited liquidity, and intraday volatility may be significant, while industry policies such as centralized procurement and price reductions may impact the company's profitability. The technical signals are somewhat positive, but further confirmation of increased volume is needed

Technical Forecast

ORBUSNEICH

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

AKESO

Pre-market trend | ORBUSNEICH (6929.HK) 5/11 Medical devices warming up, are low-level bullish signals emerging?

Penghua CSI HK Connect Health Care Composite ETF(513700.SH)